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The Journal of Immunology
Human L-Ficolin Recognizes Phosphocholine Moieties of
Pneumococcal Teichoic Acid
Emilie Vassal-Stermann,*,†,‡ Monique Lacroix,*,†,‡ Evelyne Gout,*,†,‡ Emmanuelle Laffly,*,†,‡
Christian M. Pedersen,x Lydie Martin,*,†,‡ Ana Amoroso,{ Richard R. Schmidt,‖,#
Ulrich Za¨hringer,** Christine Gaboriaud,*,†,‡ Anne-Marie Di Guilmi,*,†,‡,1 and
Nicole M. Thielens*,†,‡,1
Human L-ficolin is a soluble protein of the innate immune system able to sense pathogens through its fibrinogen (FBG) recognition
domains and to trigger activation of the lectin complement pathway through associated serine proteases. L-Ficolin has been previously
shown to recognize pneumococcal clinical isolates, but its ligands and especially its molecular specificity remain to be identified. Using
solid-phase binding assays, serum and recombinant L-ficolins were shown to interact with serotype 2 pneumococcal strain D39 and
its unencapsulated R6 derivative. Incubation of both strainswith serum triggered complement activation, asmeasured byC4b andC3b
deposition, which was decreased by using ficolin-depleted serum. Recombinant L-ficolin and its FBG-like recognition domain bound
to isolated pneumococcal cell wall extracts, whereas binding to cell walls depleted of teichoic acid (TA) was decreased. Both proteins
were also shown to interact with two synthetic TA compounds, each comprising part structures of the complete lipoteichoic acid mol-
ecule with two PCho residues. Competition studies and direct interactionmeasurements by surface plasmon resonance identified PCho
as a novel L-ficolin ligand. Structural analysis of complexes of the FBG domain of L-ficolin and PCho revealed that the phosphate
moiety interacts with amino acids previously shown to define an acetyl binding site. Consequently, binding of L-ficolin to immobilized
acetylated BSAwas inhibited by PCho and synthetic TA. Binding of serumL-ficolin to immobilized synthetic TA and PCho-conjugated
BSA triggered activation of the lectin complement pathway, thus further supporting the hypothesis of L-ficolin involvement in host
antipneumococcal defense. The Journal of Immunology, 2014, 193: 5699–5708.
T
he Gram-positive encapsulated bacterium Streptococcus
pneumoniae, although part of the respiratory commensal
flora, is the leading agent of pneumonia and serious
infections like meningitis and sepsis, every year causing ∼11% of
all deaths in children under 5 y of age (1). The transition from
asymptomatic nasopharyngeal carriage to invasive infectious state,
although poorly understood, is likely dependent on the host’s in-
nate immune response.
An important actor of host antibacterial innate immune defense is the
complement system, which is activated through three enzymatic cas-
cades, the classical, the lectin, and the alternative pathways (2–4). The
classical pathway is initiated by C1q, which binds to microbes, either
directlyor throughother immunemolecules suchasAbsandpentraxins.
The lectin pathway is activated through recognition of microbial car-
bohydrate surface motifs by oligomeric proteins including the C-type
lectins mannan-binding lectin (MBL) and the recently identified col-
lectin CL-K1 (also called collectin-11) and ficolins. Three of these
lectin-like fibrinogen (FBG)-related proteins, called M-, L-, and
H-ficolins (or ficolin-1, ficolin-2, and ficolin-3) have been identified in
humanswhereas rodents have only twoficolins, termedA andB,which
are structurally and functionally related to L- and M-ficolins, respec-
tively (5, 6).We contributed to the deciphering of the ligand recognition
specificities of the human ficolins by solving the crystal structures
of FBG domains complexed with various compounds including
N-acetylated sugars and neutral carbohydrates (7, 8). A single con-
served ligand binding site (S1)was identified inM- andH-ficolins,with
homology to the acetyl binding site of horseshoe crab tachylectin
5A. Three unique binding sites (S2–S4) were identified in L-ficolin,
allowingaccommodationofgalactose (S2) andsmall acetylated ligands
in various orientations (S2 and S3), whereas S3 and S4 sites define
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together an extended recognition surface for elongated glycans such as
the four-residue linear 1,3-b-D-glucan molecule (7). Ficolins, together
with MBL and CL-K1, associate through their collagen stalks with
MBL-associated serine protease (MASP)-1 and MASP-2, and the
resulting complexes are able to activate the complement cascade upon
binding tomicrobes (9). Complement activation leads tomicroorganism
elimination through opsonophagocytosis, inflammation, and cytolysis
while instructing an adaptive immune response. The alternative
pathway is initiated by deposition of C3b on microbial surfaces and
amplifies the other two pathways.
The complement system is of particular importance in innate
immunity to S. pneumoniae. Indeed, mouse infection models
pointed out the important role of the classical pathway (10) and
the amplification function of the alternative pathway (11). The
contribution of the lectin pathway has been probed only recently
with the demonstration that mice deficient in MASP-2 are highly
susceptible to pneumococcal infection because of a defect in
S. pneumoniae opsonization and clearance (12). Furthermore, mice
deficient in ficolin A and/or B display increased susceptibility to
S. pneumoniae infection, thus strengthening the importance of the
lectin pathway in immune response to pneumococcal infections
(13). In addition, it was shown that mouse ficolin A, human
L-ficolin, and CL-K1 but not MBL are the innate immune recog-
nition molecules that trigger activation of the lectin complement
pathway on the pneumococcal surface (12).
In the present work, we aimed to identify L-ficolin ligand(s)
exposed at the pneumococcal surface. We report that L-ficolin
binds to teichoic acids (TA) and that this interaction triggers
activation of the lectin complement pathway. L-Ficolin dis-
plays specific affinity for phosphocholine (PCho) residues, which
decorate pneumococcal TA. The crystal structure of L-ficolin
complexed with PCho was solved and showed that the PCho
phosphate group fits into the acetyl binding site S3. Altogether,
our data identified PCho as a novel L-ficolin ligand, which might




Phosphocholine (PCho) chloride calcium salt tetrahydrate, FITC, Tween 20,
acetylated BSA (AcBSA), BSA, gelatin, and laminin were purchased from
Sigma-Aldrich (Saint Quentin Fallavier, France). PCho-BSA (high loaded)
was obtained from Biosearch Technologies (Novato, CA). Rabbit poly-
clonal anti-human C3 was purchased from Abcam (ab97462).
Recombinant human MBL, produced and purified as previously de-
scribed (14), was provided by NatImmune (Copenhagen, Denmark).
Recombinant human full-length L-ficolin was produced in Chinese ham-
ster ovary cells and purified using a one-step affinity chromatography on
N-acetylcysteine–Sepharose (15). The molar concentration of tetrameric
L-ficolin was estimated using a Mr value of 406,300, and an absorbance
coefficient at 280 nm (A1%, 1 cm) of 17.6 (15). The FBG domain of
L-ficolin was produced in a baculovirus-insect cells system and purified as
previously described (7) with the following modification. The pooled
fractions from the anion–exchange chromatography were dialyzed against
50 mM triethanolamine-HCl and 145 mM NaCl (pH 7.4), concentrated to
0.6 mg/ml by ultrafiltration (Vivaspin Ultra4, Millipore, Molsheim,
France), and applied to a 1-ml heparin–Sepharose 6 Fast Flow column (GE
Healthcare). The flow-through fractions were collected and concentrated to
1 mg/ml by ultrafiltration. The molar concentration of the FBG domain
was determined using an absorption coefficient at 280 nm (A1%, 1 cm) of 22
and a Mr value of 78,000 (16).
Pneumococcal strains
S. pneumoniae R6 is an avirulent unencapsulated strain, derivative of
strain R36A, which itself derives from the capsular type 2 clinical isolate
strain D39. R6 strain was cultivated under anaerobic conditions in Todd
Hewitt (TH) broth (BD Biosciences) and the D39 strain in TH broth
supplemented with 0.5% yeast extract. Whenever required, pneumo-
cocci were fixed by 4% paraformaldehyde for 1 h in ice before ex-
tensive washes in PBS.
Isolation of pneumococcal cell wall
Cell wall purification from S. pneumoniae R6 was adapted from Ref. 17.
Briefly, a 2-l culture in TH was incubated at 30˚C until reaching an OD600
of 0.5. Cells were harvested by centrifugation for 10 min at 4˚C at 7500 3 g
and resuspended in 40 ml ice-cold water. The cell suspension was poured
dropwise into 40 ml boiling 8% SDS and boiled for 45 min. Insoluble
polymeric peptidoglycan was pelleted by centrifugation at 40,000 3 g for
20 min at 20˚C. The pellet was washed with water until it was free of SDS.
All centrifugation steps were performed at 40,000 3 g. The pellet was
resuspended in 40 ml 20 mM phosphate buffer (pH 6.9) and 7 mM NaCl,
and 200 mg/ml of a-amylase was added. Samples were incubated for 3 h at
20˚C, with gentle shaking and then centrifuged for 60 min at room tem-
perature. The pellet was resuspended in 40 ml 100 mM Tris (pH 8), and
200 mg/ml trypsin was added. Samples were incubated for 18 h at 25˚C
with gentle shaking and then centrifuged for 60 min at room temperature.
The pellet was resuspended in 40 ml 100 mM Tris (pH 7.5), and 500 mg/ml
pronase was added. Samples were incubated for 3 h at 40˚C and then
centrifuged for 60 min at room temperature. The pellet was washed three
times with cold water. At this step, samples were split, and half of the
pellet was treated with 49% hydrofluoridric acid during 48 h at 4˚C to
remove teichoic acids, a procedure shown previously to remove .99% of
the TA from the purified cell wall of different bacterial species (18, 19).
Hydrofluoridic acid was removed by centrifugation, and both cell wall
preparations, the acid treated and nontreated, were washed twice with
20 ml 8 M LiCl and then twice with 20 ml 100 mM EDTA (pH 8). Cell
walls were finally washed three times with water before being resuspended
in 2 ml water and conserved at 4˚C until use.
Synthetic LTA from S. pneumoniae
Synthetic LTA (compounds CMP 261 and CMP 197) was synthesized and
characterized as described previously (20, 21).
Solid-phase binding assays
Solid-phase binding assays were performed to measure binding of L-ficolin
and of its FBG domain to purified cell wall and synthetic LTA compounds.
Gelatin was used to coat control wells and as a blocking solution because of
the known strong background binding of purified L-ficolin to BSA-coated
and BSA-blocked ELISA plates (22). White 96-well microtiter plates
(Greiner Bio-One, Courtaboeuf, France) were coated with fixed pneumo-
cocci, 2.5 mg LTA CMP 261 or CMP 197, 100 mg pneumococcal cell wall,
and 2.5 mg gelatin/well in 100 ml TBS (20 mM Tris-HCl and 150 mM
NaCl [pH 7.4]) overnight at 4˚C. Wells were blocked with 0.2% gelatin
in TBS for 2 h at room temperature, washed with TBS and varying amounts
of L-ficolin, its FBG domain or normal human serum (NHS) diluted in
TBS containing 0.02% gelatin (TBS-gelatin) were added and incubated
for 2 h at room temperature. After washing with TBS, L-ficolin binding
was detected by incubation for 1 h at 37˚C with a rabbit polyclonal Ab
against the L-ficolin FBG domain (diluted 1/1,000 in TBS-gelatin).
After five washes with TBS, HRP-conjugated anti-rabbit IgG (Sigma-
Aldrich) diluted 1/20,000 in TBS-gelatin was added and incubated for
1 h at 37˚C. After washing with TBS, ECL solution (Pierce) was added
and chemiluminescence was measured using a multiwell luminescence
reader (Fluostar Optima, BMG Labtech). In the case of detection of
serum L-ficolin and when appropriate, TBS containing 2 mM CaCl2 was
used.
Binding of L-ficolin to paraformaldehyde-fixed pneumococci was mea-
sured using the same assay with the following modifications. To ensure
efficient deposition of fixed pneumococci, the microplates were briefly
centrifuged (500 3 g) before overnight incubation at 4˚C. Three washes
were used throughout the procedure. Incubations with the primary and
secondary Abs for detection of binding of purified or serum L-ficolin to
fixed pneumococci were performed at room temperature.
Bacterial binding assays
Black 96-well microtiter plates (Greiner Bio-One, Courtaboeuf, France)
were coated with 1 mg (in 100 ml PBS) of L-ficolin, L-ficolin FBG domain,
MBL, laminin, and BSA overnight at 4˚C. Wells were blocked with 1%
BSA in PBS for 1 h at room temperature. Pneumococci from the R6 strain
were labeled with FITC as described previously (23), added to each well
(1.85 3 108 labeled bacteria in 50 ml PBS, BSA 0.2%), and incubated for
2 h at 37˚C. After 15 washes with 200 ml PBS, 100 ml PBS was added, and
the fluorescence signal was read using a multiwell luminescence reader
(Fluostar Optima; BMG Labtech).
5700 L-FICOLIN INTERACTION WITH PNEUMOCOCCAL TA
 at U
niv M









Surface plasmon resonance analyses and data evaluation
Surface plasmon resonance (SPR) analyses were performed on a BIAcore
3000 instrument (GE Healthcare) at 25˚C. AcBSA, BSA, and L-ficolin
were diluted to 25 mg/ml in 10 mM sodium formate (pH 3), 10 mM so-
dium acetate (pH 4), and 10 mM sodium acetate (pH 5), respectively, and
immobilized on a CM5 sensor chip in 10 mM HEPES, 145 mM NaCl,
0.005% surfactant P20 (GE Healthcare) (pH 7.4) (HBS-P) using the amine
coupling chemistry, according to the manufacturer’s instructions (GE
Healthcare). Binding was measured at a flow rate of 20 ml/min in 145 mM
NaCl, 50 mM Tris-HCl (pH 7.4), and 0.005% surfactant P20 (TBS-P) or in
HBS-P containing 2 mM CaCl2 (HBS-P-Ca). Sixty microliters of each
soluble analyte at desired concentrations were injected over the immo-
bilized ligands. A flow cell submitted to the coupling steps without im-
mobilized protein or with immobilized BSA was used as a blank for
immobilized L-ficolin or AcBSA, respectively. The specific binding signal
was obtained by subtracting the background signal over the blank surface.
For competition assays, L-ficolin was incubated for 20 min at room tem-
perature in the presence of various concentrations of competitor before
injection. The signal recorded for the competitor alone was subtracted
from the data. Regeneration of the surfaces was achieved by 10-ml
injections of 1 M NaCl and 10 mM EDTA (pH 7.4).
Steady-state affinity for PCho binding to immobilized L-ficolin was
calculated from equilibrium responses (Req) obtained by injecting five to
eight PCho concentrations ranging from 0.25 to 10 mM (Req versus con-
centration data) using the BIAevaluation 3.2 software (GE Healthcare).
Buffer blanks were subtracted from the data sets used for analysis. The
quality of the fits is assessed by the x2 value, which is a standard sta-
tistical measure of the closeness of the fits. Typical values are in the same
order of magnitude as the noise in resonance units (RUs) (below 5) and/or
,10% of the maximal binding capacity of the surface (90 RU in our
particular case).
Lectin complement pathway activation assays
Ficolin-deficient serum was obtained by incubating 3 ml NHS from
a healthy donor with 1 ml AcBSA–Sepharose for 3 h at 4˚C as described
previously (15). Microtiter plates (Maxisorp Nunc) were coated with 100
ml BSA, AcBSA, PCho-BSA, or synthetic LTA CMP 197 (100 mg/ml) in
PBS overnight at room temperature. Wells were washed with PBS con-
taining 0.05% Tween 20 (w/v) (PBS-T) and incubated for 1 h at 37˚C with
PBS containing 1% BSA (w/v). Ficolin-deficient serum diluted 1:25 in 5
mM sodium veronal, 145 mM NaCl, 5 mM CaCl2, and 1.5 mM MgCl2
(pH 7.5) was reconstituted with increasing concentrations of recombinant
L-ficolin, added to the wells, and incubated on ice for 1 h. The wells were
washed with 5 mM sodium veronal, 145 mM NaCl, and 5 mM EDTA
(pH 7.5), and then, an in-house rabbit polyclonal Ab raised against purified
C4 (1:1000 dilution) was added to each well and incubated for 1 h at
room temperature. After washing with PBS-T and incubation with a
peroxidase-conjugated goat anti-rabbit polyclonal Ab (Sigma-Aldrich) (di-
luted 1:20,000 in PBS-T) for 1 h at room temperature, plates were washed
and developed with tetramethylbenzidine (Tebu-Bio Laboratories). The re-
action was stopped with 1 N H2SO4, and absorbance was read at 450 nm.
Complement activation by fixed bacteria was measured with the fol-
lowing modifications. Dulbecco’s PBS with Ca and Mg (Invitrogen) was
used for bacteria coating and washing, saturation was performed with 0.2%
gelatin in Dulbecco’s PBS at room temperature for 2 h, and incubation
with 1:100 diluted NHS or ficolin-depleted human serum was performed at
room temperature for 1 h. A rabbit anti-C4 or -C3 polyclonal Ab (1:1000
dilution) was used as primary Ab and, after incubation with the secondary
HRP-conjugated Ab, ECL solution (Pierce) was added, and chemilumi-
nescence was measured using a multiwell luminescence reader (Fluostar
Optima; BMG Labtech).
Crystallization, structure determination, and refinement
Crystals of the L-ficolin fibrinogen domain were grown as described pre-
viously (7). Briefly, they were obtained using the hanging drop vapor dif-
fusion method, by mixing equal volumes (2 ml) of the protein solution and
of a reservoir solution composed of 15% (w/v) PEG 8000, 200 mM calcium
acetate, and 0.1 M HEPES (pH 7). Soaking was performed overnight at
20˚C, with a final concentration of 100 mM PCho, taking into account the
final addition of 1 ml cryoprotectant PEG 400. Diffraction data up to 2.2 A˚
were recorded at the European Synchrotron Radiation Facility ID23-eh1
beamline. They were integrated using XDS (24) in the P3221 space group.
The structure was solved unambiguously by molecular replacement using
Phaser, with the L-ficolin FBG trimer as a search model (25). Refine-
ment was performed with REFMAC (26) up to 2.25 A˚ resolution, using
bulk solvent correction and Translation/Libration/Screw-motion refine-
ment, alternating with graphic inspections and modeling using the Coot
software (27).
Results
Serum and recombinant L-ficolins bind to R6 and D39
pneumococcal strains
Binding of human L-ficolin to serotype 2 D39 and unencapsulated
R6 strains was investigated using a solid-phase binding assay to
investigate a putative role of the capsule polysaccharides for
L-ficolin binding. Microtiter plates were coated with fixed pneu-
mococci and incubated with various NHS dilutions or varying
amounts of purified recombinant L-ficolin. L-ficolin binding was
detected by reaction with a polyclonal anti–L-ficolin Ab. Dose-
dependent binding of serum L-ficolin to both D39 and R6 strains
was observed (Fig. 1A), showing that the interaction could occur
in the absence of the pneumococcal polysaccharidic capsule. In
accordance with these results, purified recombinant L-ficolin
interacted with both pneumococcal strains (Fig. 1B). Incubation
of NHS (1%) with the coated bacteria resulted in deposition of
both C4b and C3b fragments (Fig. 1C, 1D), indicative of com-
plement activation. Use of ficolin-depleted serum instead of NHS
resulted in 67 and 76% decreased C4b deposition on the R6 and
D39 strains, respectively (Fig. 1C), providing evidence for the
involvement of the ficolin-dependent lectin complement pathway.
Under the same conditions, C3b deposition was also significantly
reduced (53–54%) (Fig. 1D), in accordance with previous studies
showing that mouse serum deficient in ficolin A impaired C3b
deposition on fixed S. pneumoniae D39 (12).
The L-ficolin–pneumococcus interaction was also analyzed in
the reverse configuration by incubating soluble FITC-labeled R6
bacteria with coated proteins BSA and laminin serving as negative
and positive controls, respectively (23). As shown in Fig. 1E, the
bacteria bound to both recombinant L-ficolin and its FBG domain,
indicating that the interaction involves the recognition domain of
L-ficolin. The lower interaction signal observed with the FBG
domain is expected because binding of L-ficolin to its ligands should
be more efficient than binding of the isolated recognition domain
because of the avidity component of the interaction with the oligo-
meric full-length protein. No significant interaction was obtained
with MBL, in accordance with previous studies and with the reported
lack of MBL involvement in pneumococcus opsonization (12, 28).
L-ficolin binds to pneumococcal cell wall
Apart from the capsule, the pneumococcal cell wall is composed of
peptidoglycan (PGN) and teichoic acid (TA). The latter encom-
passes carbohydrate polymers either membrane-anchored (lipo-
teichoic acids, LTA) or associated to the PGN (wall teichoic acids,
WTA). To investigate the contribution of TA and PGN moieties to
L-ficolin binding, we used isolated pneumococcal cell walls either
containing or lacking TA following chemical acidic treatment. As
shown in Fig. 2, purified L-ficolin interacted with microplate-
coated cell wall, and the binding was decreased by 30% when
cell wall devoid of TA was used. Comparable results were ob-
tained using the FBG domain of L-ficolin: the binding was de-
creased by 49% in the absence of TA. The residual binding to the
cell wall depleted of TA likely arises from the contribution of
N-acetylated carbohydrate units of the PGN to the interaction with
L-ficolin, although the presence of residual traces of TA after
hydrofluoridric acid treatment of the cell wall cannot be excluded.
These data demonstrate that TA contributes significantly to the
interaction of L-ficolin with the pneumococcal cell wall and fur-
ther indicate that the interaction is mediated by the recognition
domain of L-ficolin.
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L-ficolin binds to synthetic pneumococcal TA
Analysis of the molecular determinants of L-ficolin interaction
was performed using synthetic LTA forms, based on the R6
LTA structure. The backbone of pneumococcal TA is composed
by a pentameric repeating unit consisting of a ribitolphosphate
linked to a tetrasaccharide moiety including N-acetyl-galactos-
amine (GalNpAc), 2-acetamido-4-amino-2,4,6-trideoxyGalNAc,
and glucose (Glc) residues. The GalNpAc residues are terminal
and contain two PCho groups each in position O6 (29). The com-
pound CMP 197 corresponds to this pentasaccharide unit (which—
contrary to previous publications—is not identical to the repeating
unit) and which lacks a phosphate group at the ribitol representing
the terminal nonreducing end (20) (Fig. 3A). CMP 261 is the
glycophospholipid form because the pentasaccharide unit is connected
to a trisaccharide composed of Glc and 2-acetamido-4-amino-
2,4,6-trideoxyGalNAc residues attached to the hydrophobic car-
bon chain providing the membrane anchorage of LTA (20)
(Fig. 3A). CMP 261 and CMP 197 were coated on a microtiter
plate and incubated with varying amounts of purified recombinant
L-ficolin or its FBG domain. Dose-dependent binding of recom-
binant L-ficolin (Fig. 3B) and the FBG domain (Fig. 3C) to both
compounds was observed, demonstrating that synthetic pneumo-
coccal LTA is a ligand of L-ficolin and that the pentasaccharide
unit (CMP 197) contains the motifs required for L-ficolin binding.
In accordance with these results, serum L-ficolin did interact with
CMP197 (Fig. 3D). The CMP 197–L-ficolin interaction was also
demonstrated by SPR spectroscopy, using the immobilized re-
combinant protein and the soluble ligand, which yielded a weak,
although reproducible binding signal when injected at 6 and 33 mM
(data not shown).
To identify the TA residues involved in the interaction, the binding
of the FBG domain to CMP 261 was measured in the presence of
100 mM of various carbohydrates, which compose the TA moiety
such as Glc and GalNAc, and of PCho. Mannose, which is not known
as an L-ficolin ligand and is absent from TA, was used as a negative
control. No significant inhibition was observed in the presence of
mannose andGlc, whereas FBG bindingwas decreased by 42%when
GalNAc was added in the mixture (Fig. 3E). The latter data are in
accordance with our previous structural studies, showing the spec-
ificity of L-ficolin for acetylated ligands like GalNAc (7). Binding of
L-ficolin to Glc had been observed previously in the particular
context of b1-3 glucan, an elongated Glc tetramer interacting in a
highly specific manner with both S3 and S4 sites, whereas no inter-
action was observed with the Glc monosaccharide (7), in accordance
with the absence of competition observed with Glc. Interestingly, the
presence of 100 mM PCho resulted in a more important decrease
(58.3%) in FBG binding (Fig. 3E). Altogether, these results suggest
that saccharidic groups such as GalNAc are potentially involved in
the interaction of L-ficolin FBG domains with pneumococcal LTA
and that PCho might represent a new L-ficolin ligand.
FIGURE 1. Interaction of human serum and recombinant L-ficolin with pneumococcal D39 and R6 strains. Paraformaldehyde-fixed D39 or R6 bacteria
(107 CFU) were coated on a microtiter plate and incubated with NHS (A) or purified recombinant human L-ficolin (B). Bound L-ficolin was detected with
a polyclonal anti–L-ficolin Ab and is expressed in chemiluminescence arbitrary units (AU). The signal on control wells coated with 2.5 mg gelatin was
subtracted from the obtained values. Results are means 6 SD of triplicates and are representative of two independent experiments. (C and D) Fixed D39 or
R6 bacteria (107 CFU) were incubated with 1% normal (NHS) of ficolin-depleted (Dficolin) human serum and C4b (C) and C3b (D) deposition were
detected by chemiluminescence. Results are expressed as means 6 SD of three independent experiments performed in duplicate. Comparisons between
data obtained with NHS and Dficolin were made using a paired Student t test; two-tailed p values are 0.0051 (R6) and 0.0103 (D39) for C4b deposition and
0.0012 (R6) and 0.0035 (D39) for C3b deposition. (E) One microgram of the indicated proteins was coated on a microtiter plate and incubated with FITC-
labeled R6 bacteria (1.85 108 CFU). Binding is expressed in fluorescence AU, and results are means 6 SD of four independent experiments performed in
triplicate. Comparisons between binding of bacteria to BSA and each other protein were made using an unpaired Student t test; two-tailed p values are
,0.001 (L-ficolin and laminin), 0.0051 (FBG), and 0.243 (MBL). p , 0.05 is considered significant. *p , 0.05, **p , 0.005.
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Phosphocholine is a ligand of L-ficolin
The direct interaction of PCho with L-ficolin was first investigated
by SPR spectroscopy, using soluble PCho and immobilized re-
combinant L-ficolin. Injection of various concentrations of PCho
(0.5–10 mM) over the L-ficolin surface yielded Req (Fig. 4A) that
allowed determination of steady-state affinity by plotting Req
versus PCho concentration (Fig. 4B). A resulting KD value of 4.1
mM was obtained for the experiment presented in Fig. 4B and of
3.7 mM in a second independent experiment (data not shown),
with x2 values of 3.2 and 4.5, respectively, indicative of a good
match of the experimental data to the binding model.
Phosphocholine binds to the S3 ligand binding site of L-ficolin
We next investigated more precisely how L-ficolin FBG domain
binds to PCho. This was achieved by soaking FBG crystals into
solutions containing various PCho concentrations (30, 100, 150,
and 300 mM), as previously reported for other L-ficolin ligands (7).
Electron densities corresponding to PCho were clearly observed in
all conditions. We report in this study the structure corresponding
to the highest resolution obtained (2.25 A˚), which was achieved by
soaking the crystal in 100 mM PCho. The crystallographic col-
lection data and final refinement statistics are listed in Table I. The
coordinates and structure factors of the L-ficolin/PCho complex
are accessible (PDB code 4NYT).
Fig. 5A shows an overall view of the trimeric fibrinogen-like
recognition domain of L-ficolin. The PCho ligand was fully sta-
bilized only in subunit A (Fig. 5A, 5B), in accordance with the
contrasted levels of crystal packing stabilization observed previ-
ously for the three protomers and their bound ligands (7). The
PCho phosphate group binds into a pocket delineated by Arg132,
Asp133, Thr136, and Lys221 (Fig. 5B), previously defined as the S3
binding subsite (7). The main electrostatic contributions driving
this interaction are probably provided by the positive charges of
the Arg132 and/or Lys221 side chains. A polar interaction network
also stabilizes the phosphate group, which interacts with the
Asp133 main chain nitrogen, the side-chain Thr136 hydroxyl and
the Lys221 amine groups (Fig. 5B). The mode of interaction of
PCho with the S3 site is highly similar to the one previously
observed for acetylcholine (AcCho) (Fig. 5C).
These structural data prompted us to investigate whether PCho
could compete for L-ficolin binding to acetylated ligands. SPR
experiments were performed to analyze the interaction of L-ficolin
with immobilized AcBSA in the presence of potential competitors.
As shown in Fig. 6A, L-ficolin binding was dose-dependently
inhibited by PCho, with 56% inhibition obtained at a concentra-
tion of 6 mM, which is compatible with the KD value of 4 mM
observed for the L-ficolin–PCho interaction (Fig. 4B). When the
same experiment was performed in the presence of CMP 197,
38.2% inhibition was obtained at a concentration of 100 mM
(Fig. 6B). These data indicate that binding of L-ficolin to CMP
197 and PCho involves the S3 acetyl binding site of the protein.
L-ficolin–dependent complement activation by TA
To test whether binding of L-ficolin to synthetic TA could trigger
activation of the lectin pathway of complement, we assayed the
capacity of L-ficolin to induce C4b deposition after incubation with
ficolin-depleted serum added to microplate wells coated with
synthetic TA, AcBSA, PCho-BSA, or BSA (Fig. 7). The addition
of increasing amounts of recombinant human L-ficolin to CMP
197, AcBSA, and PCho-BSA resulted in increased C4b deposi-
tion, whereas, as expected, BSA did not trigger the complement
cascade. Interestingly, complement activation induced by immo-
bilized CMP 197 reached a level comparable to that of AcBSA,
a well-known L-ficolin ligand (15). Although the lower amount of
C4b deposited on PCho-BSA suggests a weaker activation effi-
ciency of PCho groups in this context, these data indicate that
PCho groups are sufficient to trigger activation of the lectin
pathway through L-ficolin recognition.
Discussion
L-ficolin has been shown to recognize a broad range of bacteria,
including Gram-negative species such as Salmonella typhimurium
(30), Escherichia coli (31), and Haemophilus influenzae (32), and
Gram-positive encapsulated bacteriam including Staphylococcus
aureus (28, 33) and type III group B streptococci (GBS) (34).
L-ficolin was also reported to bind several pneumococcal strains,
like serotypes 2, 3, 6B, 11 (A, D, and F), 18 and 35 (A and C) (12,
28, 35, 36). To our knowledge, we report in this study for the first
time that serum and recombinant L-ficolins bind to unencapsu-
lated pneumococcal strain (R6) and confirm the recently reported
interaction with serotype 2 D39 encapsulated strain (12). The
bacterial L-ficolin ligands identified so far include PGN from
S. aureus (37), LTA purified from GBS, S. aureus, Bacillus subtilis,
and Streptococcus pyogenes (33), capsular polysaccharides (CPS)
from GBS (34), and pneumolysin, a toxin released by S. pneu-
moniae (38). Binding of L-ficolin to these ligands triggers acti-
vation of the lectin complement pathway and, in the case of
pneumolysin, may be used by the pathogen as an immune evasion
strategy by consuming complement away from the bacterial sur-
face (38).
However, the molecular determinants of the interaction of
L-ficolin with the pneumococcal surface remained to be identified.
Our data indicate that pneumococcal ligands are provided by TA,
although PGN also likely contributes to the recognition process
because removal of TA from the purified cell wall decreased but did
not abolish L-ficolin binding. However, it cannot be excluded that
some pneumococcal CPS might also be recognized by L-ficolin
depending on the serotype considered because putative L-ficolin
ligands such as N-acetylglucosamine, galactose, and PCho can
FIGURE 2. Binding of recombinant L-ficolin and its FBG domain to
pneumococcal cell wall. Purified pneumococcal cell wall (100 mg) with
and without TA was coated on a microtiter plate and incubated with 1 mg
recombinant human L-ficolin or 2.6 mg FBG domain. Bound L-ficolin was
detected after incubation with a polyclonal anti–L-ficolin Ab. Binding is
expressed in chemiluminescence arbitrary units (AU). The signal on
control wells coated with 2.5 mg gelatin was subtracted from the obtained
values. The data shown are means 6 SD of two independent experiments
performed in triplicate. Comparisons between binding of L-ficolin or its
FBG domain to the cell wall with and without TA were made using
a paired Student t test. Two-tailed p values are 0.0211 for L-ficolin and
0.0005 for the FBG domain; p , 0.05 is considered significant. *p , 0.05,
**p , 0.005.
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be displayed by the CPS structures (39, 40). In this respect, in-
teraction of L-ficolin with O-acetylated epitopes of serotype 11A
CPS has been reported very recently (36).
Pneumococcal TA includes LTA and WTA, both possessing
identical chain structures with repeating units each containing two
PCho residues (Fig. 3A) (29, 41). To avoid potential contamination
of natural TAwith other bacterial components, we investigated the
interaction with L-ficolin using synthetic LTA, corresponding to
the complete structure of R6 strain containing one repeating unit
linked to the lipid chain (CMP 261) and to its pentasaccharidic-
derivative CMP 197. We show in this study that L-ficolin interacts
with both components through its FBG recognition domain and
have identified their common PCho constituent as a novel L-ficolin
ligand.
We have investigated PCho recognition by solving the X-ray
crystal structure of a complex of the FBG domain of L-ficolin
(7) with this ligand. Binding involves the PCho phosphate moi-
ety and the S3 binding site of L-ficolin. This site includes polar
and charged amino acid residues (Arg132, Asp133, Thr136, and
Lys221; Fig. 5B) previously shown to constitute the major L-ficolin
FIGURE 3. Binding of human L-ficolin to synthetic LTA from S. pneumoniae. (A) Scheme of synthetic TA compounds CMP 261 and CMP 197 used in
this study. (B–D) CMP 261 and CMP 197 (2.5 mg) were coated on a microtiter plate and incubated with recombinant human L-ficolin (B), recombinant FBG
domain (C), or with NHS (D). Bound L-ficolin and FBG domain were detected with a polyclonal anti–L-ficolin Ab and data are expressed in chemilu-
minescence arbitrary units (AU). The signal on control wells coated with 2.5 mg gelatin was subtracted from the obtained values. Results are means 6 SD
of triplicates and are representative of two independent experiments. (E) Binding of the FBG domain (2.6 mg) to synthetic LTA (CMP 261, 2.5 mg) was
measured in the absence and presence of 100 mM monosaccharides or PCho. The data shown are means 6 SD of two independent experiments performed
in triplicate and are expressed relative to the control signal obtained in the absence of competitor (Ctrl). Comparisons between binding obtained in the
absence and in the presence of each competitor were made using an unpaired Student t test; Two-tailed p values are 0.264, 0.0681, 0.0358, and 0.0167 for
mannose (Man), Glc, GalNAc, and PCho. *p , 0.05 is considered significant.
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binding site for acetylated ligands, including acetylcholine (7).
Two oxygen atoms of the phosphate group are involved in elec-
trostatic interactions, leaving the third oxygen pointing away from
the binding pocket. This orientation would allow accommodation
of a PCho-bearing ligand with the phosphate group in ester link-
age with carbohydrates as present in pneumococcal TA chains
(42). This hypothesis is further supported by the fact that site S3 is
located on the external face of the FBG trimer in an area shown
previously to participate together with the adjacent site S4 in
defining an elongated binding surface for the linear Glc tetra-
saccharide b-D-glucan (7). It should also be mentioned that TA
chains are decorated with multiple PCho groups since they are
made of four to eight repeating units, each containing two PCho
FIGURE 4. Analysis by SPR spectroscopy of the interaction of PCho
and LTA CMP 197 with immobilized L-ficolin. (A) Sixty ml of PCho at
concentrations of 0.5, 1, 2, 5, and 10 mM (from bottom to top) were
injected over immobilized L-ficolin (16,600 RU) in 10 mM HEPES, 145
mM NaCl, 2 mM CaCl2, (pH 7.4), and 0.005% surfactant P20 at a flow rate
of 20 ml/min. The specific binding signals shown were obtained by sub-
tracting the background signal over a reference surface with no protein
immobilized and further subtraction of buffer blank injection. (B) Deter-
mination of the KD by steady-state affinity fitting of the plot of the Req
against PCho concentration.
Table I. Crystallographic data and refinement statistics
Space Group P3221
Unit cell lengths (A˚) a = 96.1, b = 96.1, c = 139.9
Resolution (A˚) 20–2.2
Rsym 8.1 (52)a
% Completeness 99.5 (99.5)a
I/s (I) average 20.13 (4.14)a








Root mean square deviation
x2 bonds (A˚)
0.018
Root mean square deviation
x2 angles (˚)
1.89
Ramachandran statistics No. of residues in the favored
region: 593 (93.5%)c
No. of residues in the allowed
region: 40 (6.3%)c
No. of residues in the outlier
region: 1 (0.2%)c
aStatistics for the high-resolution bin (2.26–2.20 A˚) are in parentheses.
bStatistics for the high-resolution bin (2.31–2.25 A˚) are in parentheses.
cIncluding prolines and glycines—statistics provided by RAMPAGE.
FIGURE 5. Unveiling the PCho binding site in the recognition domain
of L-ficolin. (A) Side view of the homotrimeric X-ray structure. Nt indi-
cates the N-terminal end of each protomer (A–C), named and colored
accordingly. The complete PCho ligand bound to protomer A and its
phosphate moiety (PO4) bound to protomer C are labeled and displayed in
sticks. Ca2+ ions are represented as golden spheres. The carbohydrate
chain linked to Asn215 is colored yellow green and labeled “glyco.” Act,
acetate molecules bound to the external “S1” site. (B) PCho binding in
protomer A. The Arg132, Asp133, Thr136, and Lys221 residues, defining the
S3 subsite, are shown in sticks. Polar interactions are displayed as dashed
red lines. The corresponding electron density map is shown in gray. Some
water molecules are shown as red spheres. (C) AcCho binding in the S3
site (2J0H PDB code) is shown for comparison purposes in an orientation
similar to (B).
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residues (29). This could allow simultaneous interaction of this
multivalent ligand with more than one protomer within a FBG
trimer or with several recognition domains within full-length
oligomeric L-ficolin. Although our SPR experiments yielded an
L-ficolin binding KD in the 10
24 and 1023 M range for CMP 197
and PCho, respectively, these values likely do not reflect the af-
finity of the interaction of L-ficolin with PCho in the physiological
context of the bacterial surface, which should be strengthened
through avidity. The fact that L-ficolin saccharidic ligands such as
GalNAc were shown to compete for L-ficolin–CMP 261 interac-
tion might arise from the fact that these ligands participate, to-
gether with PCho, to L-ficolin binding and/or that they compete
for binding to L-ficolin S3 site. Interestingly, the fact that the
phosphate moiety binds to the same site as acetylated ligands
raises the possibility that L-ficolin could bind phosphate groups in
the context of other polysaccharide chains such as DNA, a known
L-ficolin ligand at the surface of apoptotic cells (43, 44). This
capacity to accommodate various ligands using the same binding
site likely contributes to the observed recognition versatility of
L-ficolin.
Our study identifies L-ficolin as a novel member of the family of
host PCho-binding proteins, including platelet-activating factor
receptor, involved in pneumococcal adhesion and invasion of host
cells (45), innate immune proteins such as the scavenger receptor
CD36 (46) and C-reactive protein (CRP) (47), and Abs/myeloma
proteins (48). Crystal structure data available for complexes of
PCho with the Fab of mouse myeloma protein M603 and CRP
reveal different binding modes of this ligand. PCho was shown to
occupy a small part of the Ag binding pocket of M603 Fab, with
the choline moiety buried and the phosphate located at the surface,
interacting with residues of the H chain (49). The PCho binding
site of CRP involves two protein-bound Ca2+ ions, each coordi-
nated by an oxygen of the phosphate group, and an adjacent
choline-binding pocket contributed from acidic and hydrophobic
residues (50). CRP is a doughnut-shaped pentameric protein,
with the five PCho binding sites located on a face of the pentamer,
thus allowing multivalent ligand binding. Although the structural
determinants of the interaction of a CRP protomer with PCho are
clearly different from those of the L-ficolin FBG domain, multi-
valent binding of both full-length proteins to PCho-containing
bacterial TAs is expected to involve avidity, a distinctive feature
of pattern recognition by many innate immune receptors.
S. pneumoniae LTA was suggested previously to trigger in-
flammation through interaction with the innate immune receptor
TLR-2, but it was found later that this activity could not be
reproduced with synthetic LTA and arose from contamination of
natural LTA with bacterial lipopeptides (51, 52). Pattern recogni-
tion proteins of the lectin complement pathway were proposed as
possible innate immune receptor candidates for LTA, but experi-
mental evidence was lacking so far. In the current study we show
that L-ficolin recognizes pneumococcal TA, more particularly its
PCho groups and that L-ficolin interaction with synthetic TA and
PCho-BSA conjugate triggers activation of the lectin complement
pathway. This approach allowed for the molecular characteriza-
tion of L-ficolin–ligands interactions that might play a role in the
physiological context of the pneumococcus. However, it should be
considered that L-ficolin recognition and complement activation
efficiency will largely depend on the presentation of the potential
ligands at the bacterial surface and on the avidity component of
the interactions.
Binding of CRP to the PCho groups of pneumococcal TA has
been reported to trigger activation of the classical complement
pathway through C1q recruitment (53). However, CRP-mediated
protection of mice from pneumococcal infection was proposed
recently to be independent from this complement activating ca-
pacity of CRP (54). L-ficolin–mediated complement activation
through direct binding to the PCho groups of TA would provide
the host with a specific antipneumococcal defense mechanism that
could contribute to the critical role of L-ficolin–dependent lectin
pathway emphasized in two recent in vivo studies (12, 13).
FIGURE 6. SPR analysis of the competition of PCho (A) and syn-
thetic LTA (CMP 197) (B) for L-ficolin binding to immobilized AcBSA.
L-Ficolin (2 nM) was injected over immobilized AcBSA (650 RU) in the
absence or presence of the indicated concentrations of PCho or CMP 197
in 145 mM NaCl, 50 mM Tris-HCl (pH 7.4), and 0.005% surfactant P20 at
a flow rate of 20 ml/min. The specific binding signals shown were obtained
by subtracting the background signal over a reference surface with
immobilized BSA (1350 RU) and further subtraction of the signal obtained
by injecting PCho or CMP 197 in the absence of L-ficolin.
FIGURE 7. Activation of the L-ficolin–dependent lectin complement
pathway by TA compound CMP 197 and PCho-BSA. CMP 197, BSA,
AcBSA, and PCho-BSA (10 mg) were coated on a microtiter plate.
Recombinant L-ficolin was mixed with 4% ficolin-depleted serum and
added to the wells (0, 0.25, 0.5, 1, 2, and 4 mg/ml for BSA, AcBSA and
CMP 197 and 0, 1 2, and 4 mg/ml for PCho-BSA). The cleaving activity of
activated MASP-2 was measured using a C4b deposition assay. Results are
expressed as means 6 SD of duplicates and are representative of two to
four independent experiments.
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Although the presence of surface PCho molecules is a feature
shared by many respiratory tract bacterial pathogens (reviewed in
Ref. 55), a specificity of S. pneumoniae resides in the presence of
WTA-linked choline-binding proteins. Binding of these proteins
to PCho residues of TA might modulate PCho exposure at the
pneumococcal surface and consequently S. pneumoniae interac-
tion with host innate immune proteins including L-ficolin and
CRP. Such a modulation has been proposed previously for the
PCho groups of the LPSs of Haemophilus influenzae (56) and
Neisseria (57) and could thus participate in a general bacterial
strategy to regulate host innate immune recognition. Besides, it
should be mentioned that PCho groups are also known to con-
tribute to pneumococcal virulence by aiding in adherence of
S. pneumoniae to host cells (58, 59). The fine-tuning of PCho
distribution at the bacterial surface is thus likely participating to
the bacterial adaptation to various environments and L-ficolin–
PCho recognition might play a role in the multiple mechanisms
involved in the delicate balance between host protection and
pathogen immune evasion/invasion.
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